Leap Therapeutics' Board of Directors Member Dr. Monica Bertagnolli Appointed as the Director of the National Cancer Institute
Leap Therapeutics, Inc. (Nasdaq:LPTX) announces the transition of Board member Dr. Monica Bertagnolli, recently appointed as the 16th Director of the National Cancer Institute (NCI), marking the first woman to hold this position since 1937. Effective immediately, Dr. Bertagnolli steps down from Leap's Board, following a commendable tenure. The company expresses pride in her achievement, recognizing her significant contributions to cancer research and leadership. Leap Therapeutics focuses on immuno-oncology therapeutics, notably developing DKN-01 for various cancers in partnership with BeiGene, Ltd.
- Dr. Bertagnolli's appointment to NCI could foster future collaborations or insights beneficial to Leap's strategic direction.
- Her extensive experience in cancer research may strengthen Leap's future therapeutic developments.
- Dr. Bertagnolli's departure may create a gap in leadership experience and continuity on the Board.
Dr. Bertagnolli to Transition Off Leap's Board of Directors
CAMBRIDGE, Mass., Aug. 12, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics today announced that its Board member, Monica Bertagnolli, MD, has been appointed as the 16th Director of the National Cancer Institute (NCI) by the Biden administration. Dr. Bertagnolli becomes the first woman director of the institute since its inception in 1937. Effective with her appointment, Dr. Bertagnolli will transition off Leap's Board of Directors.
"On behalf of Leap Therapeutics, we are extremely proud of Monica and congratulate her for being selected for this prestigious position at the NCI," said Douglas E. Onsi, President and Chief Executive Officer of Leap. "Monica is a renowned surgeon and leader in cancer research, and we are extremely grateful for her counsel in guiding our organization to where we are today. We thank her for all of her contributions to Leap and look forward to her leadership of the Cancer Moonshot and the development of new therapies for cancer patients."
Dr. Bertagnolli is currently a professor of surgery at Harvard Medical School, and an associate surgeon at Brigham and Women's Hospital and Dana-Farber Cancer Institute. She also serves as the current President of American Society of Clinical Oncology (ASCO). Dr. Bertagnolli is the group chair of Alliance for Clinical Trials in Oncology, and President of the Alliance for Clinical Trial in Oncology Foundation and CEO of Alliance Foundation Trials, LLC. She has previously served as Chief of the Division of Surgical Oncology at Dana Farber/Brigham and Women's Cancer Center (2008-2018) and was an attending surgeon at New York Presbyterian Hospital – Weill Cornell from 1994-1999. Dr. Bertagnolli has served on numerous committees and boards including the Board of Directors for ASCO and the National Academy of Medicine's National Cancer Policy Forum.
About Leap Therapeutics
Leap Therapeutics (Nasdaq: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. DKN-01 is being developed in patients with esophagogastric, gynecologic, and colorectal cancers. Leap has entered into a strategic collaboration with BeiGene, Ltd. for the rights to develop DKN-01 in Asia (excluding Japan), Australia, and New Zealand. For more information about Leap Therapeutics, visit http://www.leaptx.com or view our public filings with the SEC that are available via EDGAR at http://www.sec.gov or via https://investors.leaptx.com/.
CONTACT:
Douglas E. Onsi
President & Chief Executive Officer
Leap Therapeutics, Inc.
617-714-0360
donsi@leaptx.com
Matthew DeYoung
Investor Relations
Argot Partners
212-600-1902
leap@argotpartners.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/leap-therapeutics-board-of-directors-member-dr-monica-bertagnolli-appointed-as-the-director-of-the-national-cancer-institute-301604629.html
SOURCE Leap Therapeutics, Inc.
FAQ
What does the appointment of Dr. Monica Bertagnolli mean for Leap Therapeutics?
Who is replacing Dr. Bertagnolli on Leap Therapeutics' Board?
How might Dr. Bertagnolli's new role affect Leap Therapeutics?
What is Leap Therapeutics focusing on?
